Skip to main content

Vasculitis

      Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
      For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management. Whilst previously there was a sense that a “low” GC dose with limited duration was used, we now appreciate just how heterogenous the disease course of PMR can be, with many patients experiencing frequent relapses and garnering a subsequent huge GC burden over a number of years.
      JAK/TYK Topic Panel from ACR
      Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.
      Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
      The Case for JAKi in PMR
      Day 4 Recap: ACR 2024
      Hypoxia seems to exacerbate neutrophil activation by ANCA

      - enhanced F-Actin polymerization
      - enhanced NET formation

      Brian Jaros, MD Dr_Brian_MD

      9 months 1 week ago
      Hypoxia seems to exacerbate neutrophil activation by ANCA - enhanced F-Actin polymerization - enhanced NET formation Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns? @RheumNow #ACR24 https://t.co/KxaeMvkd2t
      Hydralazine - known culprit of drug-induced AAV

      How does hydral (H) AAV differ from primary (1) AAV?
      💥 High dual pos

      Brian Jaros, MD Dr_Brian_MD

      9 months 1 week ago
      Hydralazine - known culprit of drug-induced AAV How does hydral (H) AAV differ from primary (1) AAV? 💥 High dual positivity MPO/PR3 💥 DAH / pleuritis more common in H-AAV 💥 ENT, constitutional, nervous, ILD in 1-AAV 💥 More 6mo remission in H-AAV @rheumnow #ACR24 Abst 2496
      SELECT-GCA suggests JAKis may be the new kid on the block

      Clinicians treating giant cell arteritis (GCA) have long had

      Dr. John Cush RheumNow

      9 months 1 week ago
      SELECT-GCA suggests JAKis may be the new kid on the block Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY
      The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. This approach is not well individualized to the patient as we do not account for the degree of inflammation that may or may not be present in the disease. Improved markers to stratify the extent of inflammation can help
      Day 3 Recap: ACR 2024
      ×